MET expression

Indeed, orthotopic implantation of MET-expressing GBM cells corroborates their superior tumor-initiating and invasive capabilities. Thus, pericytes represent critical modulators of GBM development by orchestrating a tumor-suppressive microenvironment, highlighting the importance of their preservation in therapy.

These data suggest that c-Met protein OE is associated with MET mRNA expression, shows limited overlap with other MET aberrations, and may be linked to poor prognosis in NSCLC.

P1/2, N=231, Recruiting, Regeneron Pharmaceuticals | Active, not recruiting --> Recruiting

Collectively, this study elucidates the molecular mechanism by which the HAND1/c-MET axis regulates EC progression through the modulation of FAO. This provides a novel perspective for understanding the pathogenesis of EC and offers potential biomarkers for developing novel diagnostic and therapeutic strategies for EC.

Specifically, our study demonstrated: (1) The MET gene is significantly overexpressed in THCA tissues compared to normal controls; (2) This dysregulation is closely associated with aggressive malignant phenotypes, including enhanced tumor progression, increased metastatic potential, reduced survival, and immune-suppressive characteristics; (3) Retrospective clinical case analysis indicated that the lymph node metastasis rate was significantly elevated in the MET high-expression group relative to the low-expression group; (4) RNA interference (RNAi)-mediated MET knockdown resulted in a marked decrease in the migratory and invasive capacities of thyroid cancer cells in vitro. Collectively, these findings not only identify MET as a robust molecular classifier for THCA but, more critically, uncover its therapeutic potential as an actionable target within the HGF/c-MET axis for refractory THCA, providing both experimental evidence and a theoretical framework for developing precision diagnostic and therapeutic strategies.

The aberrant expression of HGF/MET and BMPs is related to lymphatic metastasis in breast cancer. Integrated expression level of MET/BMP-15/matriptase-1 and the inversed HAI-1/BMP-3/matriptase-2 establishes a predictive model for lymph node involvement.

P2, N=270, Active, not recruiting, AbbVie | Trial primary completion date: Oct 2025 --> Jul 2026

P=N/A, N=50, Not yet recruiting, The Affiliated Hospital of Guilin Medical University; The Affiliated Hospital of Guilin Medical University

In summary, HRA00129-C004 is a superior c-Met ADC with relatively low affinity to c-Met, efficient internalization, and strong bystander effect. It is currently being investigated in a Phase I clinical trial for patients with advanced solid tumors.

When compared to a CD3 bispecific with the same c-Met binder, ABBV-303 drove lower levels of inflammatory cytokines at equivalent levels of tumor cell killing and enhanced tolerance of normal cells expressing c-Met, consistent with the natural tendency of NK cells to preferentially react with stressed or cancer cells as compared to normal, healthy tissue. Together, this study showed that ABBV-303 is effective at driving anti-tumor immunity against a wide range of c-Met expressing tumors.

The c-Met/PD-1 CAR-T cells were successfully constructed and demonstrated significant in vitro and in vivo killing effects on ECA109 esophageal cancer cells.

Additionally, it examines current therapeutic approaches targeting c-Met, including small molecule inhibitors, monoclonal antibodies, and combination therapies designed to overcome resistance. The discussion extends to future challenges in c-Met inhibition, highlighting the need for innovative therapeutic strategies and combination regimens to enhance efficacy and mitigate resistance and thus the review emphasizes the transformative potential of c-Met-targeted therapies in advancing cancer treatment.